Seattle Genetics Drug Passes Safety Test, Trial Continues
Luke Timmerman12/10/08
Seattle Genetics said today its experimental drug for acute myeloid leukemia passed an interim safety review. The Bothell, WA-based biotech company (NASDAQ: SGEN) said an independent monitoring committee recommended the study continue of lintuzumab (SGN-33). Full results from the trial, which is two-thirds of the way to its enrollment goal of 210 patients, should be available in the first half of 2010, the company said.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
